Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Xencor, Inc. (XNCR : NSDQ)

• Company Description    Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. Number of Employees: 250

• Price / Volume Information    Yesterday's Closing Price: $11.59 Daily Weekly Monthly 20 Day Moving Average: 523,873 shares Shares Outstanding: 71.41 (millions) Market Capitalization: $827.65 (millions) Beta: 0.98 52 Week High: $18.69 52 Week Low: $6.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.38% -8.01% 12 Week -26.97% -29.46% Year To Date -24.30% -24.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 465 NORTH HALSTEAD STREET SUITE 200 - PASADENA,CA 91107 USA ph: 626-305-5900 fax: 626-305-0350 investors@xencor.com http://www.xencor.com

• General Corporate Information    Officers Bassil I. Dahiyat - Chief Executive Officer; President and Director Bart Jan Cornelissen - Sr. Vice President & Chief Financial Officer A. Bruce Montgomery - Director Kurt Gustafson - Director Kevin C. Gorman - Director Peer Information Xencor, Inc. (GSAC) Xencor, Inc. (CASI) Xencor, Inc. (ALCD.) Xencor, Inc. (OMNN) Xencor, Inc. (CGPI.) Xencor, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 98401F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 71.41 Most Recent Split Date: (:1) Beta: 0.98 Market Capitalization: $827.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.66 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.64 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.32 Price/Cash Flow: - Price / Sales: 5.51 EPS Growth vs. Year Ago Period: 88.73% vs. Previous Quarter: 80.49% Sales Growth vs. Year Ago Period: 96.07% vs. Previous Quarter: -51.85% ROE 12/31/25 - - 09/30/25 - -20.44 06/30/25 - -25.75 ROA 12/31/25 - - 09/30/25 - -14.52 06/30/25 - -18.19 Current Ratio 12/31/25 - - 09/30/25 - 5.99 06/30/25 - 5.34 Quick Ratio 12/31/25 - - 09/30/25 - 5.99 06/30/25 - 5.34 Operating Margin 12/31/25 - - 09/30/25 - -87.14 06/30/25 - -121.52 Net Margin 12/31/25 - - 09/30/25 - -87.14 06/30/25 - -121.52 Pre-Tax Margin 12/31/25 - - 09/30/25 - -86.56 06/30/25 - -122.54 Book Value 12/31/25 - - 09/30/25 - 8.76 06/30/25 - 8.72 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©